Roche and SystemsX collaborate in diabetes research

December 14, 2005

Roche and the Competence Center for Systems Physiology and Metabolic Diseases (CC-SPMD) of SystemsX, the Swiss Initiative in Systems Biology, today announced a three-year research partnership. Scientists from Roche and the CC-SPMD will participate in a joint research project entitled «Systems biology of the beta cell-application to type 2 diabetes progression». The project aims to identify novel pathways for drug development in diabetes as well as new biomarkers of beta cell failure for diagnostics. Beta cells which are located in the isles of Langerhans in the pancreas produce and release the hormone insulin, controlling the level of glucose (sugar) in the blood.

A team of more than 15 scientists at Roche and the CC-SPMD, including researchers from the Swiss Federal Institute of Technology in Zurich (ETH Zurich) and University of Zurich, will collaborate and exchange research results. The project will be financed by Roche at a cost of 2.1 million Swiss francs each year for three years.

"This new, systems-oriented research approach, the integration of several disciplines and collaboration of outstanding scientists from academia and industry will allow us to obtain new insights into the dysregulation of beta cells and their impact on type 2 diabetes progression. We intend to translate this knowledge into innovative treatment options for patients," said René Imhof, Head of Pharma Research, Basel.

«This holistic approach should prove that the whole is stronger than the sum of the parts and ultimately replace the key physiological pathways at the center of our attention, which is critical for our understanding of metabolic disorders», said Jacques Mizrahi, Global Therapy Area Head of Metabolic and Vascular Diseases, at Roche.

"I am very pleased that such a promising collaboration between a SystemsX project and Roche became reality so fast," said Prof. Ernst Hafen, President of the ETH Zurich and Chairman of the Board of Directors of SystemsX. Prof. Alexander Borbély, Vice-President Research at the University of Zurich, emphasised: "The early incorporation of clinical scientists from the University of Zurich is a good example of an integrative approach to major scientific issues in medicine." And Willy Krek, Professor of Cell Biology at the ETH Zurich and Director of the CC-SPMD, said: "Working closely together with Roche we have designed an exciting project that will accelerate the effective conversion of basic discoveries into evidence-based therapies."
-end-
About Systems Biology
Systems Biology is a new discipline that addresses the analysis of entire biological systems. Rather than analysing individual components of a cell, Systems Biology is focusing on all components and their interacting networks at the level of genes, proteins, biochemical reactions and physiological processes. It is based on the growing understanding of how biological systems interact dynamically to give rise to physiological functions. Understanding complex biological and physiological interactions can help scientists find new ways to detect, prevent and treat multi-factorial and polygenic diseases such as diabetes. Type 2 diabetes Health experts have warned of a global epidemic of diabetes caused by a rise in overweight and obesity. There are currently 120-140 million people worldwide with type 2 diabetes, and if trends continue, this number is predicted to double in the next 25 years. In the Western world, around 90% of type 2 diabetes cases are attributable to weight gain. Because of the severe health and cost implications of this disease, organisations such as the International Diabetes Federation (IDF) have called for increased efforts to prevent its development. The IDF estimates that 314 million people worldwide, or 8.2% of the global population, have impaired glucose tolerance, a state that often precedes type 2 diabetes.

About the Competence Center for Systems Physiology and Metabolic Diseases
The Competence Center for Systems Physiology and Metabolic Diseases (CC-SPMD) is a multi-disciplinary research collaboration between the ETH Zurich and the University of Zurich, created to bring the power of Systems Biology to physiology and medicine. The CC-SPMD brings together scientists from different disciplines, including biology, computer science, chemistry and medicine, to study metabolic control networks of different biosystems and their dynamic behaviour in health and disease. Additional information about the CC-SPMD is available on the Internet (www.cc-spmd.ethz.ch).

About SystemsX
The CC-SPMD is a Scientific Node of SystemsX, the Swiss Initiative in Systems Biology. The institutions participating in the initiative are the ETH Zurich, the University of Basel and the University of Zurich. It is envisaged that further Swiss universities will join SystemsX to build up a globally competitive, national research network in Systems Biology. Scientific Nodes like the CC-SPMD are devoted to specific scientific questions in Systems Biology and have one of the SystemsX universities as their lead institution. Besides Scientific Nodes, SystemsX intends to build up so-called Glue Projects. These overarching technology platforms are planned to do research in computer science, data management, imaging, genomics, proteomics and other technologies relevant to Systems Biology. The Glue Projects are intended to interface with all the scientific nodes of SystemsX. For more information on SystemsX, see www.systemsx.ch.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet (www.roche.com).

SystemsX.ch

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.